Project Image:
Title of the project:
Defeating the SARS-CoV-2 epidemic requires the timely generation of the clinical and epidemiological data for defining targeted public health measures at the national and global level.
As part of this project, the NMI will use differential serolomics to assess sero-prevalence, cross and pre-existing immunity against coronaviruses.
Project leader:
Dr. Nicole Schneiderhan-Marra
Project funding:
  • HORIZON 2020
Funding reference number:

Two months after the first reports of the current outbreak of SARS-CoV-2, some of the most basic elements for risk assessment and targeted control measures are still unknown. CORESMA aism to directly address this need through unique mHealth, high resolution serolomics, and complementary approaches of mathematical modelling, artificial intelligence and implementation research in an ad-hoc implementation mode, including countries likely to be particularly affected or vulnerable.

For this purpose, the Multiplex Immunoassays Group at the NMI, in partnership with the HZI, will develop a multiplex serotest for SARS-CoV-2 to measure the seroprevalence of pre-existing cross and/or partial immunity in samples from the general population of Germany and Nepal. Any assay developed shall then undergo continuous development to track the ongoing evolution of SARS-CoV-2.

For further details please view

Project partners:
  • Helmholtz Centre for Infection Research (Germany), NMI, Rijksinstituut voor Volksgezondheid en Milieu (Netherlands), Swiss Tropical and Public Health Institute (Switzerland)